The Catalyst Brief
Week of September 21–27, 2026
Editor's Note
This week's reporting showed buyers paying for position before the risk had cleared. Telix agreed to pay $1.65 billion upfront for ITM, six weeks after the FDA rejected ITM's lead drug on manufacturing grounds. ADARx priced an upsized IPO, with AbbVie buying in alongside public investors. Genentech paid upfront for Earendil's AI-driven antibody design. Lilly and Cordis won FDA approvals that bring new formats into established treatment markets, and Amgen posted a Phase 3 win in a disease with no approved drug. Capital followed execution capacity as closely as clinical data.
Top Stories
Telix Buys ITM for $1.65 Billion Upfront, Six Weeks After an FDA Rejection
The Catalyst Brief – September 21, 2026
Summary:
Telix agreed to acquire ITM Isotope Technologies Munich for $1.65 billion upfront, plus up to $700 million in milestones tied to ITM-11, a radioligand therapy for gastroenteropancreatic neuroendocrine tumors. On August 10, the FDA rejected ITM-11, citing manufacturing issues and items from an inspection of a third-party commercial facility. ITM plans to refile. Up to $250 million of the milestones depends on FDA approvals and up to $450 million on sales. ITM, a lutetium-177 supplier, reported $273 million in 2025 sales, and Telix expects the combined company to generate more than $1.3 billion this year.
Why it matters:
Telix is buying isotope supply and manufacturing as well as a late-stage asset, in a market where Novartis already has established products. The deal ties $700 million of the price to ITM-11's approvals and sales, so the sellers share the regulatory risk.
FDA Approves Lilly's Onswik, the Second Once-Weekly Insulin in the U.S.
The Catalyst Brief – September 25, 2026
Summary:
On September 24, Eli Lilly said the FDA approved Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes. Lilly says it means more than 300 fewer injections a year than daily insulin. Approval rests on the Phase 3 QWINT trials in more than 3,400 adults, which showed non-inferiority to once-daily insulin glargine and insulin degludec. The label says Onswik should not be used in type 1 diabetes because of an increased risk of low blood sugar. It is Onswik's fourth approval, after Europe, Mexico and Japan, and Lilly expects U.S. availability in the coming months.
Why it matters:
Novo's Awiqli became the first once-weekly insulin on the U.S. market in March, so Lilly enters as a fast follower. With efficacy set at parity with daily insulin, the contest turns on launch execution and adherence.
ADARx Prices an Upsized $446.3 Million IPO as AbbVie Buys In
The Catalyst Brief – September 25, 2026
Summary:
ADARx Pharmaceuticals, a San Diego RNA biotech, priced 26.25 million shares at $17 in an upsized Nasdaq IPO, raising $446.3 million, above its earlier plans. AbbVie committed $100 million in a concurrent private placement that will leave it with about 4.9% of the company. Proceeds go first to agazisiran, a complement factor B siRNA in Phase 2 studies across several complement-mediated diseases, and to Phase 3 development of onvuzosiran in hereditary angioedema. The company's chief financial officer said investors were drawn to a broad pipeline of five internally generated, wholly owned candidates.
Why it matters:
The IPO window is open, but selectively. A platform with several wholly owned programs and a large-pharma partner deepening its stake cleared the bar with room to spare. Strategic backing lowers financing risk; development risk remains.
Genentech Pays Earendil $55 Million Upfront for AI-Designed Cancer Bispecifics
The Catalyst Brief – September 25, 2026
Summary:
Genentech will pay Earendil Labs $55 million upfront to discover and develop bispecific antibody programs in oncology, in a collaboration that could exceed $1.5 billion with development, regulatory and sales milestones, plus tiered royalties. Earendil leads discovery and early clinical work on pre-agreed target combinations; Genentech then takes over global development and commercialization. Neither company disclosed the targets. Earendil says its AI-driven platform generates antibody sequences at scale and predicts their properties to optimize molecules. The deal follows a $787 million private round in March backed by Sanofi, among others.
Why it matters:
A multi-program structure lets a large drugmaker buy design capacity without betting on one asset. For AI-enabled platforms, repeat upfront payments from major partners are becoming the evidence that the tools improve development efficiency.
Amgen's Dazodalibep Wins Phase 3 in Sjögren's, a Disease With No Approved Drug
The Catalyst Brief – September 23, 2026
Summary:
Amgen said dazodalibep, a fusion protein targeting the CD40 ligand, met the primary endpoint of the Phase 3 OASIZ 301 study in Sjögren's disease, an autoimmune condition that attacks the tear and salivary glands. After 48 weeks, patients on the drug had significantly improved scores on the ESSDAI disease-activity index versus placebo. The most common side effects included nasal inflammation, urinary tract infection, hypertension and infusion-related reactions, mostly mild or moderate. Detailed results are due at an upcoming medical conference. A second Phase 3 study, OASIZ 303, enrolls patients with milder systemic disease.
Why it matters:
No medicine is specifically approved by the FDA for Sjögren's, so a consistent late-stage result carries commercial weight. William Blair expects the FDA to want two positive Phase 3 trials, making OASIZ 303 the gating readout.
FDA Approves Cordis's Selution SLR, the First U.S. Sirolimus Drug-Eluting Balloon
The Catalyst Brief – September 23, 2026
Summary:
On September 21, Cordis said the FDA approved its Selution SLR drug-eluting balloon for coronary in-stent restenosis, where treatment fails inside a previously placed stent. Cordis calls it the first and only sirolimus drug-eluting balloon cleared for that use in the U.S. The device was designated a Breakthrough Device and delivers sirolimus without leaving a permanent implant. Approval rests on a study of more than 400 patients in the U.S., Canada, Brazil and Europe, compared with standard care that included 80% drug-eluting stents. Cordis says about 10% of roughly 1 million annual U.S. coronary interventions address in-stent restenosis.
Why it matters:
The device gives physicians a drug-delivery option that can reduce the need for another stent. Cordis has finished enrolling a 960-patient study against stents in small coronary vessels, positioning this approval as a first U.S. step.
Market & Investment Pulse
Radiopharma consolidation now covers supply. Telix is paying $1.65 billion upfront for ITM, a lutetium-177 supplier, and placing up to $700 million of contingent value on ITM-11's path through the FDA.
Manufacturing setbacks are being priced, not avoided. ITM-11's rejection cited manufacturing and facility items, and Telix tied a large share of the price to approval and sales milestones rather than walking away.
The IPO window rewards breadth and backing. ADARx raised more than it first planned, and AbbVie's $100 million placement added strategic support to public demand.
AI-enabled discovery is earning through partnerships. Earendil's $55 million upfront and tiered royalties show a large drugmaker paying for platform output across several programs, not a single asset.
Convenience is a competitive axis. Onswik enters a once-weekly insulin category Novo opened in March. Selution SLR offers drug delivery without a permanent implant.
Open indications carry premium value. Dazodalibep's Phase 3 win comes in Sjögren's disease, where no medicine is specifically FDA-approved, though a second trial still has to confirm it.
What to Watch Next Week
ITM's timing for refiling ITM-11, which depends on manufacturing remediation and talks with the FDA.
Onswik's U.S. launch, which Lilly expects in the coming months.
Full OASIZ 301 results for dazodalibep at an upcoming medical conference.
Cordis's 960-patient small-vessel study, which the company plans to use in a future FDA application.
Closing
Every story above draws on The Catalyst Brief's reporting this week. Deal terms, manufacturing readiness and trial design each shaped the probability of success. Read the full analysis at thecatalystbrief.com.
Thank you for reading The Catalyst Brief!
For deeper coverage, explore the full articles linked above. Feel free to forward this brief to colleagues or reply with feedback—your input helps us continue delivering biotech intelligence that improves decision-making and increases the probability of success.